Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci

Teresa M. Coque; Kavindra V. Singh; Barbara E. Murray

doi:10.1093/jac/37.5.1011

Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci

Teresa M. Coque, Kavindra V. Singh, Barbara E. Murray

Houston Methodist

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

The in-vitro activities of the new fluoroquinolone trovafloxacin (CP-99,219) and ciprofloxacin were determined against 225 Gram-positive cocci. Trovafloxacin was 4-32 fold more active than ciprofloxacin against staphylococci and streptococci and also showed greater activity against enterococci including vancomycin resistant Enterococcus faecium and Enterococcus faecalis that were highly resistant to aminoglycosides and/or produced β-lactamase. Trovafloxacin was also bactericidal at 3 mg/L against enterococci except for isolates for which the MICs were ≥ 2 mg/L.

Original language	English (US)
Pages (from-to)	1011-1016
Number of pages	6
Journal	Journal of Antimicrobial Chemotherapy
Volume	37
Issue number	5
DOIs	https://doi.org/10.1093/jac/37.5.1011
State	Published - May 1996

ASJC Scopus subject areas

Pharmacology
Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1093/jac/37.5.1011

Cite this

@article{61f05c1b2c5d4141bad3dedf197ad401,

title = "Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci",

abstract = "The in-vitro activities of the new fluoroquinolone trovafloxacin (CP-99,219) and ciprofloxacin were determined against 225 Gram-positive cocci. Trovafloxacin was 4-32 fold more active than ciprofloxacin against staphylococci and streptococci and also showed greater activity against enterococci including vancomycin resistant Enterococcus faecium and Enterococcus faecalis that were highly resistant to aminoglycosides and/or produced β-lactamase. Trovafloxacin was also bactericidal at 3 mg/L against enterococci except for isolates for which the MICs were ≥ 2 mg/L.",

author = "Coque, {Teresa M.} and Singh, {Kavindra V.} and Murray, {Barbara E.}",

note = "Funding Information: The authors acknowledge the grant given by the Roerig division of Pfizer Inc Groton, CT, USA and the support given to Teresa M. Coque by the Subprograma de Formation de Personal Investigador en el Extranjero (Section Doctores y Tecnologos) del Ministerio de Education y Ciencia, Spain. This work was presented in part at the 34th Interstience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, USA 1994.",

year = "1996",

month = may,

doi = "10.1093/jac/37.5.1011",

language = "English (US)",

volume = "37",

pages = "1011--1016",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci

AU - Coque, Teresa M.

AU - Singh, Kavindra V.

AU - Murray, Barbara E.

N1 - Funding Information: The authors acknowledge the grant given by the Roerig division of Pfizer Inc Groton, CT, USA and the support given to Teresa M. Coque by the Subprograma de Formation de Personal Investigador en el Extranjero (Section Doctores y Tecnologos) del Ministerio de Education y Ciencia, Spain. This work was presented in part at the 34th Interstience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, USA 1994.

PY - 1996/5

Y1 - 1996/5

N2 - The in-vitro activities of the new fluoroquinolone trovafloxacin (CP-99,219) and ciprofloxacin were determined against 225 Gram-positive cocci. Trovafloxacin was 4-32 fold more active than ciprofloxacin against staphylococci and streptococci and also showed greater activity against enterococci including vancomycin resistant Enterococcus faecium and Enterococcus faecalis that were highly resistant to aminoglycosides and/or produced β-lactamase. Trovafloxacin was also bactericidal at 3 mg/L against enterococci except for isolates for which the MICs were ≥ 2 mg/L.

AB - The in-vitro activities of the new fluoroquinolone trovafloxacin (CP-99,219) and ciprofloxacin were determined against 225 Gram-positive cocci. Trovafloxacin was 4-32 fold more active than ciprofloxacin against staphylococci and streptococci and also showed greater activity against enterococci including vancomycin resistant Enterococcus faecium and Enterococcus faecalis that were highly resistant to aminoglycosides and/or produced β-lactamase. Trovafloxacin was also bactericidal at 3 mg/L against enterococci except for isolates for which the MICs were ≥ 2 mg/L.

UR - http://www.scopus.com/inward/record.url?scp=0029903277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029903277&partnerID=8YFLogxK

U2 - 10.1093/jac/37.5.1011

DO - 10.1093/jac/37.5.1011

M3 - Article

C2 - 8737152

AN - SCOPUS:0029903277

SN - 0305-7453

VL - 37

SP - 1011

EP - 1016

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 5

ER -

Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this